Loading clinical trials...

ENROLLING_BY_INVITATIONNA

Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome

Effect of Consuming a Nutraceutical Composition Based on Pineapple and Natural Extracts on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome

NCT07103772•Universidad Autonoma de Nuevo Leon

View on ClinicalTrials.gov

Summary

Irritable bowel syndrome is characterized by the presence of chronic, recurrent abdominal pain, alterations in bowel habits, and abdominal distension. The medical diagnosis is made using the Rome IV criteria. There are three IBS phenotypes: diarrhea-predominant, constipation-predominant, and mixed.

Detailed Description

A sample of 100 people will be supplemented, with 50 participants consuming the nutraceutical gel and the remaining 50 receiving a placebo supplement. The supplementation period lasts 14 days, during which severity questionnaires and the Bristol Stool Scale will be administered on Day 0, Day 7, and Day 14. Additionally, to assess biomarkers, biochemical tests for PCR, calprotectin, and fecal lactoferrin will be conducted.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must be over 18 years old.
•Be an employee or beneficiary of UANL.
•Have gastrointestinal alterations (diarrhea, constipation, etc.) that suggest the presence of irritable bowel syndrome.
•Not be under any medical treatment.

Exclusion Criteria

•Being under medical treatment.
•Not having gastrointestinal alterations much as diarrhea, constipation, etc.
•being under 18 years old.
•Not being an employee or beneficiary of UANL.

Locations (1)

Hospital Universitario Dr. Jose Eleuterio Gonzalez

Monterrey, Nuevo León, Mexico

Key Dates

Start Date

March 14, 2024

Primary Completion Date

March 14, 2025

Completion Date

March 15, 2026

Last Updated

September 2, 2025

Enrollment

ESTIMATED participants

Conditions

Irritable Bowel SyndromeIrritable Bowel Syndrome With DiarrheaIrritable Bowel Syndrome With ConstipationIrritable Bowel Syndrome Mixed

Interventions

Ananá

DIETARY_SUPPLEMENT

Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome

NCT07481422

Irritable Bowel Syndrome (IBS)

View study

RECRUITINGNA

Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT05740319

Irritable Bowel Syndrome

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome

Inclusion Criteria

Exclusion Criteria

Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome

Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Well-being in IBS: Strengths and Happiness (WISH) 2.0

Reliability of a Food Frequency Questionnaire in the Assessment of Dietary Intake Including FODMAPs in Different Populations, and Relationship With IBS Symptoms and the Degree of Self-assessed Physical Activity

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?